HOWL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HOWL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Werewolf Therapeutics's Average Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil. Werewolf Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.74 Mil. Werewolf Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.00.
Werewolf Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2024 stayed the same from Dec. 2023 (0.00) to Dec. 2023 (0.00)
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
The historical data trend for Werewolf Therapeutics's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Werewolf Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Inventory-to-Revenue | - | - | - | - | - |
Werewolf Therapeutics Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Inventory-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Werewolf Therapeutics's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Werewolf Therapeutics's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Werewolf Therapeutics's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Werewolf Therapeutics's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
Inventory-to-Revenue (A: Dec. 2023 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) |
= | ( (0 | + | 0) | / | 1 ) | / | 19.943 |
= | 0 | / | 19.943 | ||||
= | 0.00 |
Werewolf Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2024 is calculated as
Inventory-to-Revenue (Q: Mar. 2024 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (Q: Dec. 2023 ) | + | Total Inventories (Q: Mar. 2024 )) | / | count ) | / | Revenue (Q: Mar. 2024 ) |
= | ( (0 | + | 0) | / | 1 ) | / | 0.742 |
= | 0 | / | 0.742 | ||||
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Werewolf Therapeutics (NAS:HOWL) Inventory-to-Revenue Explanation
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenueLikewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenueMore Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Werewolf Therapeutics's Days Inventory for the three months ended in Mar. 2024 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Mar. 2024 ) | / | Cost of Goods Sold (Q: Mar. 2024 ) | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Werewolf Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Mar. 2024 ) | / | Average Total Inventories (Q: Mar. 2024 ) |
= | 0 | / | 0 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Werewolf Therapeutics's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Ra Capital Healthcare Fund Lp | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Luke Evnin | director | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH STREET, BOSTON MA 02116 |
Meeta Chatterjee | director | C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142 |
Michael A. Sherman | director | 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906 |
Chulani Karunatilake | officer: Chief Technology Officer | 1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138 |
Reid Leonard | officer: Chief Operating Officer | 1030 MASSACHUSETTS AVENUE, SUITE 210, CAMBRIDGE MA 02138 |
Mpm Oncology Innovations Fund Lp | 10 percent owner | 450 KENDALL STREET, CAMBRIDGE MA 02142 |
Longwood Fund Iii Gp, Llc | 10 percent owner | 800 BOYLSTON ST, SUITE 1555, BOSTON MA 02199 |
Derek Dirocco | director | 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
Moshe Arkin | 10 percent owner | 6 HACHOSHLIM ST., HERZELIA L3 4672406 |
Alon Lazarus | director, 10 percent owner | C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421 |
Daniel J Hicklin | director, 10 percent owner, officer: See Remarks | |
Sphera Funds Management Ltd. | 10 percent owner | 4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520 |
Sphera Global Healthcare Management Lp | 10 percent owner | 4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520 |
Sphera Global Healthcare Gp Ltd. | 10 percent owner | 4 ITZHAK SADE BUILDING A, 29TH FLOOR, TEL AVIV L3 6777520 |
From GuruFocus
By sperokesalga sperokesalga • 06-01-2023
By Marketwired • 08-10-2023
By GuruFocusNews GuruFocusNews • 06-16-2022
By Value_Insider Value_Insider • 11-10-2022
By GuruFocusNews GuruFocusNews • 03-24-2022
By GuruFocusNews GuruFocusNews • 05-20-2022
By Stock market mentor Stock market mentor • 02-07-2023
By Value_Insider Value_Insider • 11-10-2022
By Marketwired • 09-11-2023
By sperokesalga sperokesalga • 04-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.